We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medifast's New Product Pipeline: Key Catalyst for Comeback?
Read MoreHide Full Article
Key Takeaways
MED is expanding beyond weight loss into metabolic health with a new science-based product line.
New offerings target visceral fat reduction while preserving lean mass and muscle health.
Management expects profitability improvement to begin in the fourth quarter of 2026 and continue into 2027.
Medifast, Inc. (MED - Free Report) is shifting from a traditional weight-loss focus toward a broader metabolic health strategy. A national survey cited by the company found that nearly 94% of American adults are concerned about at least one aspect of metabolic health, while 85% believe metabolic dysfunction can be reversed. This points to a large underserved market and supports the company’s clinically proven, coach-led approach.
Medifast is strengthening its leadership in metabolic health through ongoing research and a new product line built around its metabolic science, with the metabolic synchronization method delivering targeted metabolic reset, improving key processes and body composition in meaningful ways. At its fourth-quarter earnings call, management stated that the GLP-1 “off-ramp” is growing, with a recent study indicating that roughly two-thirds of patients come off the drugs after two years. Many of these individuals regain lost weight, and in some cases, exceed their original weight after stopping treatment.
Medifast is leveraging its metabolic synchronization science platform to develop a new product line aimed at reducing harmful visceral fat while improving body composition, metabolic efficiency and overall health. These products use a proprietary formula of clinically studied ingredients and are specifically designed to support and enhance metabolic health.
In a 16-week clinical study, participants on Medifast’s 5-in-1 metabolic plan reduced visceral fat by 14% while retaining 98% of lean mass, with the company also emphasizing muscle protection. As more consumers, particularly those transitioning off GLP-1 treatments, focus on body composition, the company’s upcoming plan, program and system aim to meet these needs. It emphasizes the quality of weight loss, removing harmful visceral fat while maintaining lean mass. This approach is generating strong excitement and confidence across Medifast’s field teams.
Medifast is seeing early results from its strategy, with improved coach productivity and emerging business bright spots. The company expects profitability improvements to begin in the fourth quarter of 2026 after launching its new product line, with continued earnings growth targeted through 2027 and beyond. Overall, Medifast’s science-led product pipeline appears central to the company’s plan to stabilize the business and work back toward growth and profitability.
Zacks Rundown for MED
This Zacks Rank #3 (Hold) company’s shares have lost 1.5% in the year-to-date period compared with the industry’s decline of 4.4%.
Image Source: Zacks Investment Research
From a valuation standpoint, MED trades at a forward price-to-sales ratio of 0.43, lower than the industry’s average of 0.75.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MED’s current fiscal-year earnings per share implies a year-over-year decline of 143.9%, while the consensus mark for the next fiscal year implies year-over-year growth of 5%.
Image Source: Zacks Investment Research
Stocks to Consider
Some better-ranked stocks have been discussed below:
The Zacks Consensus Estimate for MAMA's current fiscal-year sales & earnings implies growth of 39.9% and 44.4%, respectively, from the year-ago actuals. MAMA delivered a trailing four-quarter negative earnings surprise of 133.3%, on average.
US Foods Holding Corporation (USFD - Free Report) , together with its subsidiaries, markets, sells and distributes fresh, frozen, and dry food and non-food products to foodservice customers in the United States. USFD currently carries a Zacks Rank #2 (Buy).
The Zacks Consensus Estimate for US Foods’ current fiscal-year sales and earnings implies growth of 5.4% and 20.9%, respectively, from the year-ago actuals. USFD delivered a trailing four-quarter earnings surprise of 2.2%, on average.
B&G Foods, Inc. (BGS - Free Report) manufactures, sells, and distributes a portfolio of shelf-stable and frozen foods and household products. BGS currently carries a Zacks Rank #2.
The Zacks Consensus Estimate for B&G Foods’ current fiscal-year earnings implies growth of 5.9% from the year-ago actuals. BGS delivered a trailing four-quarter negative earnings surprise of 19.5%, on average.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Medifast's New Product Pipeline: Key Catalyst for Comeback?
Key Takeaways
Medifast, Inc. (MED - Free Report) is shifting from a traditional weight-loss focus toward a broader metabolic health strategy. A national survey cited by the company found that nearly 94% of American adults are concerned about at least one aspect of metabolic health, while 85% believe metabolic dysfunction can be reversed. This points to a large underserved market and supports the company’s clinically proven, coach-led approach.
Medifast is strengthening its leadership in metabolic health through ongoing research and a new product line built around its metabolic science, with the metabolic synchronization method delivering targeted metabolic reset, improving key processes and body composition in meaningful ways. At its fourth-quarter earnings call, management stated that the GLP-1 “off-ramp” is growing, with a recent study indicating that roughly two-thirds of patients come off the drugs after two years. Many of these individuals regain lost weight, and in some cases, exceed their original weight after stopping treatment.
Medifast is leveraging its metabolic synchronization science platform to develop a new product line aimed at reducing harmful visceral fat while improving body composition, metabolic efficiency and overall health. These products use a proprietary formula of clinically studied ingredients and are specifically designed to support and enhance metabolic health.
In a 16-week clinical study, participants on Medifast’s 5-in-1 metabolic plan reduced visceral fat by 14% while retaining 98% of lean mass, with the company also emphasizing muscle protection. As more consumers, particularly those transitioning off GLP-1 treatments, focus on body composition, the company’s upcoming plan, program and system aim to meet these needs. It emphasizes the quality of weight loss, removing harmful visceral fat while maintaining lean mass. This approach is generating strong excitement and confidence across Medifast’s field teams.
Medifast is seeing early results from its strategy, with improved coach productivity and emerging business bright spots. The company expects profitability improvements to begin in the fourth quarter of 2026 after launching its new product line, with continued earnings growth targeted through 2027 and beyond. Overall, Medifast’s science-led product pipeline appears central to the company’s plan to stabilize the business and work back toward growth and profitability.
Zacks Rundown for MED
This Zacks Rank #3 (Hold) company’s shares have lost 1.5% in the year-to-date period compared with the industry’s decline of 4.4%.
Image Source: Zacks Investment Research
From a valuation standpoint, MED trades at a forward price-to-sales ratio of 0.43, lower than the industry’s average of 0.75.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MED’s current fiscal-year earnings per share implies a year-over-year decline of 143.9%, while the consensus mark for the next fiscal year implies year-over-year growth of 5%.
Image Source: Zacks Investment Research
Stocks to Consider
Some better-ranked stocks have been discussed below:
Mama’s Creations, Inc. (MAMA - Free Report) , together with its subsidiaries, manufactures and markets fresh deli-prepared foods in the United States. MAMA currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for MAMA's current fiscal-year sales & earnings implies growth of 39.9% and 44.4%, respectively, from the year-ago actuals. MAMA delivered a trailing four-quarter negative earnings surprise of 133.3%, on average.
US Foods Holding Corporation (USFD - Free Report) , together with its subsidiaries, markets, sells and distributes fresh, frozen, and dry food and non-food products to foodservice customers in the United States. USFD currently carries a Zacks Rank #2 (Buy).
The Zacks Consensus Estimate for US Foods’ current fiscal-year sales and earnings implies growth of 5.4% and 20.9%, respectively, from the year-ago actuals. USFD delivered a trailing four-quarter earnings surprise of 2.2%, on average.
B&G Foods, Inc. (BGS - Free Report) manufactures, sells, and distributes a portfolio of shelf-stable and frozen foods and household products. BGS currently carries a Zacks Rank #2.
The Zacks Consensus Estimate for B&G Foods’ current fiscal-year earnings implies growth of 5.9% from the year-ago actuals. BGS delivered a trailing four-quarter negative earnings surprise of 19.5%, on average.